Franziska Mergel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Franziska Mergel has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ambros Johannes Beer
Department of Nuclear Medicine, University Hospital Ulm, 89081 Ulm, Germany
1 shared publication - Andreas Daniel Hartkopf
Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
1 shared publication - Angelina Fink
Department of Gynecology and Obstetrics, University Hospital Ulm, 89075 Ulm, Germany
1 shared publication - Brigitte Rack
Department of Gynecology and Obstetrics, University Hospital Ulm, 89075 Ulm, Germany
1 shared publication - Christodoulos Pipinikas
NeoGenomics, Inc., Fort Myers, FL 33912, USA
1 shared publication - Forca Mehmeti
Department of Gynecology and Obstetrics, University Hospital Ulm, 89075 Ulm, Germany
1 shared publication
Latest Publications
- Open Access
- 1 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8498
Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer
Current aftercare after early breast cancer overlooks recent evidence on circulating free tumor DNA (ctDNA). In this case report, we present a patient with low-risk hormone-receptor-positive breast cancer. ctDNA was first detected using a tumor-informed approach 12 months after the initial diagnosis and remained positive throughout adjuvant therapy with letrozole, while routine staging examinations showed no signs of relapse. Clinical relapse was ultimately identified nearly six years after the initial diagnosis, resulting in a lead time of four years and nine months. Current studies on ctDNA in the adjuvant setting have been conducted in high-risk cohorts and have shown a median molecular lead time of 8.9–12.4 months. Our study supports the need for large randomized clinical trials involving low-risk breast cancer patients to drive changes in clinical practice.
- 1 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8498
Open AccessIs Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer
Current aftercare after early breast cancer overlooks recent evidence on circulating free tumor DNA (ctDNA). In this case report, we present a patient with low-risk hormone-receptor-positive breast cancer. ctDNA was first detected using a tumor-informed approach 12 months after the initial diagnosis and remained positive throughout adjuvant therapy with letrozole, while routine staging examinations showed no signs of relapse. Clinical relapse was ultimately identified nearly six years after the initial diagnosis, resulting in a lead time of four years and nine months. Current studies on ctDNA in the adjuvant setting have been conducted in high-risk cohorts and have shown a median molecular lead time of 8.9–12.4 months. Our study supports the need for large randomized clinical trials involving low-risk breast cancer patients to drive changes in clinical practice.